Microbot Medical(MBOT)

Focus: Microbot Medical is a public biotechnology company specializing in micro-robot assisted medical technologies, currently focused on endovascular interventions and peripheral vascular device development. The company operates as a pre-revenue stage device innovator with minimal cash runway and negative net income.

Medical Devices Endovascular

Profile data last refreshed 21h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Microbot Medical

AI assessmentNot Hiring

No open roles listed right now. Follow Microbot Medical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

LIBERTY® Robotic System

Peripheral Vascular Interventions

Pre-Commercial

Lead product in development with one ongoing clinical trial; no commercial revenue to date.

Pipeline & Clinical Trials

Help build intelligence for Microbot Medical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneering robotic surgery platform with proprietary LIBERTY® System represents a differentiated technology in the high-growth endovascular market
Early-stage company offers potential for outsized equity upside if regulatory milestones and commercialization succeed
Only 3 open roles suggest selective hiring focused on critical functions (Operations, Real-World Evidence, Sales)

Watch Out For

Company is pre-revenue with $3M cash (FY2025) and $11.4M annual net losses—critical near-term financing risk exists
Minimal published research (0 publications), single clinical trial, and no clear revenue model suggest significant execution risk
Only one pipeline program at early stage with no Phase 1/2/3 traditional trial activity—regulatory pathway unclear

Generated by Claude from Microbot Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

The LIBERTY® Robotic System

Peripheral Vascular Interventions

Clinical Trials (1)

NCT06141694Assessment of Clin. Capabilities of LIBERTY® Endovascular Robotic System's Performance & Safety in Periph. Vasc. Interv.

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 1 clinical trial

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Financials (FY2025)

R&D Spend

$7M16%

Net Income

-$11M

Cash

$3M

Source: SEC 10-K Filing